SMStefan I. McDonough

Stefan I. McDonough

*This is an algorithmically generated author record based on publicly available information.

Stefan I. McDonough has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Annika B. Malmberg

    Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Danielle Johnson

    Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • David J. Matson

    Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Elma Feric

    Department of Neuroscience, Amgen Inc., Cambridge, Massachusetts, United States of America

    2 shared publications
  • Jeff McDermott

    Lilly Research Laboratories, Indianapolis, Indiana 46225

    2 shared publications
  • Anruo Zou

    Department of Neuroscience, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA

    1 shared publication

Latest Publications

  • Open Access

    Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund’s Adjuvant Models of Pain

    by David J. Matson, Darryl T. Hamamoto, Howard Bregman, Melanie Cooke, Erin F. DiMauro, Liyue Huang, Danielle Johnson, Xingwen Li, Jeff McDermott, Carrie Morgan, et al.

    While genetic evidence shows that the Nav1.7 voltage-gated sodium ion channel is a key regulator of pain, it is unclear exactly how Nav1.7 governs neuronal firing and what biophysical, physiological, and distribution properties of a pharmacological Nav1.7 inhibitor are required to produce analgesia. Here we characterize a series of aminotriazine inhibitors of Nav1.7 in vitro and in rodent models of pain and test the effects of the previously reported “compound 52” aminotriazine inhibitor on the spiking properties of nociceptors in vivo. Multiple aminotriazines, including some with low terminal brain to plasma concentration ratios, showed analgesic efficacy in the formalin model of pain. Effective concentrations were consistent with the in vitro potency as measured on partially-inactivated Nav1.7 but were far below concentrations required to inhibit non-inactivated Nav1.7. Compound 52 also reversed thermal hyperalgesia in the complete Freund’s adjuvant (CFA) model of pain. To study neuronal mechanisms, electrophysiological recordings were made in vivo from single nociceptive fibers from the rat tibial nerve one day after CFA injection. Compound 52 reduced the spontaneous firing of C-fiber nociceptors from approximately 0.7 Hz to 0.2 Hz and decreased the number of action potentials evoked by suprathreshold tactile and heat stimuli. It did not, however, appreciably alter the C-fiber thresholds for response to tactile or thermal stimuli. Surprisingly, compound 52 did not affect spontaneous activity or evoked responses of Aδ-fiber nociceptors. Results suggest that inhibition of inactivated states of TTX-S channels, mostly likely Nav1.7, in the peripheral nervous system produces analgesia by regulating the spontaneous discharge of C-fiber nociceptors.


  • Open Access

    Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to Pain

    by Jacinthe Gingras, Sarah Smith, David J. Matson, Danielle Johnson, Kim Nye, Lauren Couture, Elma Feric, Ruoyuan Yin, Bryan D. Moyer, Matthew L. Peterson, et al.

    Clinical genetic studies have shown that loss of Nav1.7 function leads to the complete loss of acute pain perception. The global deletion is reported lethal in mice, however, and studies of mice with promoter-specific deletions of Nav1.7 have suggested that the role of Nav1.7 in pain transduction depends on the precise form of pain. We developed genetic and animal husbandry strategies that overcame the neonatal-lethal phenotype and enabled construction of a global Nav1.7 knockout mouse. Knockouts were anatomically normal, reached adulthood, and had phenotype wholly analogous to human congenital indifference to pain (CIP): compared to littermates, knockouts showed no defects in mechanical sensitivity or overall movement yet were completely insensitive to painful tactile, thermal, and chemical stimuli and were anosmic. Knockouts also showed no painful behaviors resulting from peripheral injection of nonselective sodium channel activators, did not develop complete Freund’s adjuvant-induced thermal hyperalgesia, and were insensitive to intra-dermal histamine injection. Tetrodotoxin-sensitive sodium current recorded from cell bodies of isolated sensory neurons and the mechanically-evoked spiking of C-fibers in a skin-nerve preparation each were reduced but not eliminated in tissue from knockouts compared to littermates. Results support a role for Nav1.7 that is conserved between rodents and humans and suggest several possibly translatable biomarkers for the study of Nav1.7-targeted therapeutics. Results further suggest that Nav1.7 may retain its key role in persistent as well as acute forms of pain.


  • Open Access

    Calcium ion channels: challenges and successes in drug discovery

    by Stefan I. McDonough

    There are both opportunities and challenges in developing improved or novel therapeutics based on targeting voltage‐gated calcium channels. Calcium channels are technically difficult with respect to target‐based drug discovery but unquestionably are key points for influencing human physiology and pathophysiology. Many marketed drugs, including nifedipine, nimodipine, ethosuximide, pregabalin, and ziconotide, exert therapeutic efficacy via inhibition of calcium channels. Although there is no obvious path to improving these existing drugs, recent clinical results with dihydropyridine drugs point to testable strategies for treatment of Parkinson's disease and possibly other CNS disorders by inhibiting L‐type calcium channels. Roles of T‐type calcium channels in pain and in abnormal sleep are plausible and may soon be tested with clinical trials of novel therapeutics. Success with any of these trials certainly will be followed by intensive efforts for further refinements around the target class. WIREs Membr Transp Signal 2013, 2:85–104. doi: 10.1002/wmts.71For further resources related to this article, please visit the WIREs website.


  • Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Nav1.7 antagonists

    by Nagasree Chakka, Howie Bregman, Bingfan Du, Hanh Nho Nguyen, John L. Buchanan, Elma Feric, Joseph Ligutti, Dong Liu, Jeff S. McDermott, Anruo Zou, et al.